新京报讯(首席记者郭铁)第八届进博会期间，新西兰a2牛奶公司携"全家营养解决方案"参展，并与中国 农垦控股上海有限公司签署战略伙伴协议，扩大合作范围。 目前，基于A2型蛋白质在亲和肠胃、认知支持、母婴营养等维度的科学研究在全球持续展开，a2公司 也通过科研成果落地让其A2蛋白型乳品"从实验室走向家庭餐桌"。a2牛奶公司大中华区首席执行官黎 笑表示："进博会见证了a2'全家营养解决方案'的诞生、完善和升级全过程。" 本届进博会上，a2牛奶公司与中国农垦控股上海有限公司签署战略合作升级协议，双方将在原有独家进 口及分销合作基础上，进一步拓展a2新西兰原产乳品中的核心品类，通过跨境电商渠道直接带到中国。 此次进博会亮相的a2紫曜HMO(母乳低聚糖)系列婴幼儿奶粉，就是双方此次合作的试点。 a2牛奶公司首席执行官David Bortolussi表示，"进博会不仅为我们提供了一个展示新产品和科研成果的 窗口，更是一个与中国市场共建共享的重要平台。八年来，我们在这里与合作伙伴共同见证科研创新成 果的加速落地，也持续推进产品与服务的全面升级。" ...

11月7日，记者获悉厦门幼师林芳(化名)被举报携带"地贫"基因遭解聘一事有新进展。10月31日，海沧 区人社局申诉公证委员会通知林芳维持解聘，林芳对此不认可。2025年5月，林芳因被人举报携带"地 贫"基因遭解聘，申请复核后，海沧区教育局决定维持解聘。海沧区纪检、教育系统多名官员向记者透 露，解聘的根源是有人实名举报。8月5日，海沧区人社局受理申诉申请，后因案情复杂而延长审理期。 ...

Core Insights - Xiaopeng's new generation IRON robot was showcased at the "2025 Xiaopeng Technology Day," attracting significant attention [1] - Elon Musk praised the Xiaopeng robot video, indicating that Tesla and Chinese companies will lead the market, and expressed respect for Chinese competitors [1] - Xiaopeng's CEO, He Xiaopeng, expressed happiness over Musk's recent shareholder meeting success and acknowledged Tesla's achievements in robotics and Robotaxi [1] Company Developments - The IRON robot was demonstrated in a powered state, with its internal mechanical structure revealed to address concerns about the presence of a human inside [1] - The interaction between Xiaopeng and Tesla's leadership highlights a competitive yet respectful relationship in the robotics sector [1] Industry Trends - The acknowledgment from Musk suggests a growing recognition of Chinese innovation in the robotics field, indicating a potential shift in market dynamics [1] - The emphasis on robotics and automation by both companies points to an increasing focus on technological advancements in the automotive industry [1]

Core Insights - Gilead Sciences showcased multiple products at the 8th China International Import Expo, including two Asia debut products: long-acting HIV pre-exposure prophylaxis drug Lenacapavir and a new drug for primary biliary cholangitis (PBC) named Seladelpar [1][2] Group 1: Lenacapavir - Lenacapavir is a globally first-of-its-kind long-acting HIV capsid inhibitor that requires administration only twice a year, demonstrating over 99.9% effectiveness in preventing HIV based on global Phase III clinical studies [1] - Lenacapavir has received several prestigious recognitions, including being ranked first in Science magazine's "Top 10 Scientific Breakthroughs of 2024" and being included in Time magazine's "Best Inventions of 2025" [1] - The drug was approved for HIV pre-exposure prophylaxis in Hainan Boao Lecheng International Medical Tourism Pilot Zone in late June, almost simultaneously with the approval from the U.S. FDA [1] Group 2: Seladelpar - Seladelpar is an innovative drug targeting patients with primary biliary cholangitis, a chronic autoimmune liver disease recognized as a "silent killer" and included in the National Health Commission's list of rare diseases in 2023 [2] - The drug is the first global therapy that can improve biochemical indicators in PBC patients while alleviating itching symptoms, which significantly impact the quality of life [2] - Seladelpar was approved in August under Beijing's clinical urgent import policy, marking a significant step in addressing the needs of PBC patients [2] Group 3: Gilead's Market Presence - Gilead Sciences has launched 13 global innovative drugs in China over the past eight years, benefiting approximately 1.8 million patients [2] - At the expo, Gilead plans to deepen collaborations with various parties to enhance the accessibility of innovative drugs and promote standardized diagnosis and treatment [2]

Core Insights - The release of the humanoid robot IRON by XPeng Motors reflects rapid technological advancements and differentiation in the humanoid robotics industry, with significant public interest and skepticism regarding its capabilities [1] - The domestic robotics industry has seen a doubling in financing events, with 610 new financing incidents in the first three quarters of 2025, compared to 294 in the same period last year, and a total financing amount of approximately 500 billion yuan, which is 2.5 times that of the previous year [1] - The investment landscape has shifted towards a more pragmatic approach, focusing on real scenarios, customers, and orders, making it increasingly difficult to secure financing without tangible results [3][4] Industry Trends - The humanoid robotics sector is experiencing a "honeymoon period" with capital and technology, but as companies approach IPOs, the scrutiny on their commercial viability is expected to increase [8][10] - The first humanoid robots have begun to enter various applications, including industrial settings and public events, indicating a growing integration into everyday life [11] - Companies like Yushun Technology and Zhiyuan Robotics are leading the charge towards IPOs, with Yushun reporting a revenue scale of around 1 billion yuan and maintaining profitability since 2020 [8][9] Investment Dynamics - The investment community is becoming more anxious and competitive, with a rush to invest in promising projects as valuations rise rapidly [5][6] - There is a notable shift in focus from investing in core manufacturers to components and parts, as investors seek opportunities in joint modules, servo motors, and tactile sensors [6] - The market is witnessing a divergence in business models, with some companies targeting B2B applications while others explore C2C markets, which may offer higher valuations if successful [12] Market Challenges - Despite the excitement, there are concerns about inflated valuations and the sustainability of the current growth trajectory, with some investors advocating for a more cautious approach [10][12] - The industry is facing challenges in establishing a clear commercial model, with many companies still in the process of validating their business strategies and operational capabilities [12] - The need for thorough due diligence is emphasized, as investors are urged to assess financial health and operational performance before committing capital [12]

新京报讯(首席记者郭铁)第八届进博会期间，全球最大的有机乳制品生产商阿拉福兹(Arla Foods)连续第 八年参展，并带来3款全球首发产品，包括可酷优椰子味巧克力牛奶、阿尔乐欧式田园风味奶油奶酪、 原味减脂奶油奶酪。这些创新依托Arla产品研发投入与中国市场需求的融合。 阿拉福兹副总裁兼中国区负责人程悦表示："进博会不仅是全球经贸合作的重要窗口，更是我们与中国 消费者、合作伙伴深度连接的桥梁。作为进博会的'老朋友'，我们非常高兴连续八年参与其中。我们将 继续依托于进博会这一重要平台，展示新产品、新技术，并持续加码创新研发与渠道拓展，为中国家庭 提供更多满足其需求的产品。" 在婴幼儿营养领域，Arla"宝贝与我"系列整体保持增长，跨境HMO(母乳低聚糖)产品热销。有机A2产品 增速领先行业，国标产品稳步上升；Cocio可酷优巧克力奶今年针对中国市场推出椰子口味；奶油奶酪 品类在口味、包装及健康方面全面升级。在渠道布局方面，Arla拓展跨境与大贸两大渠道，并计划于明 年升级母乳低聚糖奶粉。 ...

Core Insights - The eighth China International Import Expo (CIIE) showcased Aoyou's six major imported brands and 61 products, addressing precise nutritional needs throughout the life cycle, with six products making their debut at the event [1][2] - Aoyou's brand NC launched innovative probiotics targeting nasal sensitivity and emotional sleep, featuring the new "NC Relax" probiotic using the CCFM1025 strain [1] - The brand Kabrita introduced a new high-calcium probiotic goat milk powder aimed at the elderly for bone health and digestive needs [1] - The report "Feeding Trends to Know: 2026 Infant Formula Feeding Trends" released by Kabrita indicates that premiumization and functionality are core consumer demands, with goat milk powder gaining traction due to its absorption and low sensitivity advantages [1] - Aoyou holds 11 factories globally, with three in China, six in the Netherlands, and two in Australia, selling products in over 60 countries and regions, showing strong overseas market performance [1] - Aoyou's international business revenue is projected to grow by 68.2% in 2024 and 65.7% in the first half of 2025, driven by strategic breakthroughs in the Middle East, North America, and the CIS [1] Industry Impact - Aoyou has participated in the CIIE for eight consecutive years, leveraging the event as a platform to enhance its global image and showcase the international influence of China's dairy industry [2] - The CIIE has facilitated a shorter time-to-market for Aoyou's products, reduced operational costs, and provided opportunities for finding excellent partners and expanding business scope [2]

Core Viewpoint - The domestically produced aircraft C919 has successfully completed its first commercial flight from Beijing to Hong Kong, marking a significant milestone for China's aviation industry [1] Group 1 - The flight CA101 landed smoothly at Hong Kong International Airport, showcasing the capabilities of the C919 [1] - The aircraft was honored with a water salute, a traditional gesture in the aviation industry to celebrate inaugural flights [1] - This event highlights the progress and achievements of China's efforts in developing its own large passenger aircraft [1]

新京报讯据网信中国官微消息，11月7日，国家移民局、国家网信办在2025年世界互联网大会乌镇峰会 主论坛上，联合发布外国人资讯服务App——SinoGuide。 SinoGuide旨在帮助外国人更好融入并体验中国丰富便捷的数字化服务，集政策指引、新闻资讯、生活 服务、语言辅导于一体，以中英双语为来华、在华外国人提供支付、交通、医疗、教育、资讯等领域31 个常用在线服务，覆盖入出境政策查询、停留到期提醒、汇率查询、在线支付、一键叫车、点餐外卖、 生活缴费、语言学习等高频场景，可实现中文页面一键翻译。目前，SinoGuide已在部分安卓应用商店 上架。 下一步，将持续完善SinoGuide功能，提升数字化服务便利性，帮助外国人了解中国、感受中国、爱上 中国。 ...

新京报贝壳财经讯11月7日，正泰电器（601877）发布公告称，公司股票于2025年11月5日-7日连续3个 交易日内日收盘价格涨幅偏离值累计超20%，属于股票交易异常波动情形。经自查及向控股股东和实控 人核实，截至公告披露日，公司生产经营正常，不存在应披露未披露重大信息，未发现影响股价的媒体 报道、市场传闻及重大事件。 ...